VedTechBio has announced significant advancements in its AI-powered drug discovery platform, RxAgentAI. The company aims to proactively advance discovery by compressing timelines and workflows. A 30% reduction in target and drug identification timelines and a 50% compression of full target-disease-drug analysis workflows are expected outcomes. VedTechBio is also partnering with AlphaMeld to further enhance its capabilities, with the goal of mapping rare disease landscapes in under 3 weeks, down from 12 weeks previously.